II
JAZZ icon

IFM Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

IFM Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16
Closed -$3.02K – 665
2026
Q1 		$3.02K Buy
+16
New +$2.8K ﹤0.01% 658

Other funds holding JAZZ

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BCM
BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

IFM Investors's JAZZ Position: Q2 2026 in Review

IFM Investors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 16 shares — an estimated $3.02K sold.

IFM Investors first reported a position in JAZZ in Q1 2026 and held it in 1 quarter. The position peaked at $3.02K in Q1 2026. 130 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • IFM Investors reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • IFM Investors sold 16 Jazz Pharmaceuticals shares in Q2 2026, an estimated $3.02K.
  • IFM Investors first reported a position in Jazz Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • IFM Investors's Jazz Pharmaceuticals position peaked at $3.02K in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.